Investors

RESOURCES

Funding

Find your next investment

Our ventures team maintains connections with investors around the country and the world to accelerate the growth of U-M startups. Learn more about our startup pipeline, the Accelerate Blue Fund, and how to become an Accelerate Blue Fund donor.

Accelerate Blue Fund

The Accelerate Blue Fund (ABF) is an early-stage venture fund that invests exclusively in University of Michigan licensed startups. The goal of Accelerate Blue is to bridge the funding gap between initial launch and angel/venture capital funding for startups based on University of Michigan intellectual property.

Learn more about ABF

Startup Pipeline

Interested in learning more about U-M’s startup portfolio? If you represent a venture fund, corporate venture fund, or you are an accredited investor contact us to learn more about our comprehensive list of emerging U-M startups and companies seeking investment capital.

Learn more about U-M startups

Innovation Partnerships Startup Portfolio

Research at the University of Michigan has led to the launch of high impact startups that have changed the world for the better, including Intralase, Mythic AI, Ascentage Pharma, Handylab, Ambiq Micro, May Mobility and many others.

View Portfolio

Support the Accelerate Blue Fund

Every success story that results from Accelerate Blue funding is due to the generosity and philanthropy of Alumni, friends of the University of Michigan, and our corporate partners. We are working towards our goal of raising $20 million in the Accelerate Blue Fund. To support our evergreen venture fund that accelerates the commercial growth of U-M startups, click donate today to learn more.

Donate Today

Featured Stories of Success

Momentous First Year for U-M’s Accelerate Blue Fund

In the News

It’s been another momentous year for the Accelerate Blue Fund (ABF), the evergreen investment fund for U-M startups. ABF aims to bridge the funding gap between initial launch and angel/VC funding and invests exclusively in tech startups based on licensed U-M intellectual property. The Fund is being raised through the...

EVOQ Therapeutics Announces a License and Collaboration Agreement with Amgen

Press Releases, Stories of Success

EVOQ Therapeutics today announced a license and collaboration agreement with Amgen for the discovery and development of novel drugs for autoimmune disorders. Under the terms of the agreement, Amgen and EVOQ will collaborate on preclinical development and Amgen will be responsible for clinical development and commercialization.

Research Bridge Partners’ Seed Capital Investment in Asalyxa Bio

In the News, Press Releases

Research Bridge Partners – a 501 (c) (3) organization that bridges preeminent innovators at mid-continent research universities with the commercialization resources of Silicon Valley— announced a seed capital investment in Asalyxa Bio, a University of Michigan spinout that has developed a drug-delivery technology to treat a wide range of inflammatory diseases.